johnson & johnson (JNJ) Key Developments
Johnson & Johnson Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months of 2015; Revises Earnings Guidance for the Full Year 2015
Jul 14 15
Johnson & Johnson announced unaudited consolidated earnings results for the second quarter and six months of 2015. Net earnings and diluted earnings per share for the second quarter of 2015 were $4.5 billion and $1.71, respectively against $4.326 billion and $1.78 per dilute share a year ago. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.8 billion and adjusted diluted earnings per share were $1.71, representing decreases of 6.3% and 3.9%, respectively, as compared to the same period in 2014. On an operational basis, adjusted diluted earnings per share increased 6.7%. The company announced sales of $17.8 billion for the second quarter of 2015, a decrease of 8.8% from $19.5 billion as compared to the second quarter of 2014. Earnings before provision for taxes on income was $5,741 million against $5,626 million a year ago.
For the six months, net earnings were $8,836 million against $9,053 million a year ago. Earnings before provision for taxes on income was $11,316 million against $11,050 million a year ago. Net earnings per share (diluted) was $3.13 against $3.15 a year ago. Adjusted earnings before provision for taxes and net earnings was $11,878 million against $12,452 million a year ago. Adjusted earnings per diluted share was $3.27 against $3.41 a year ago. The company announced sales of $35.161 billion against $37.610 billion a year ago.
The company increased its adjusted earnings guidance for full-year 2015 to $6.10 to $6.20 per share. The Company's guidance excludes the impact of after-tax intangible amortization expense and special items.
Johnson & Johnson Announces Investigational HIV Vaccine Regimen Shows Encouraging Results in Non-Human Primates
Jul 3 15
Johnson & Johnson announced that scientists at Beth Israel Deaconess Medical Center (BIDMC), Crucell Holland B.V and several other collaborators published results from a preclinical study of an HIV vaccine regimen used in non-human primates. The study, published in the online edition of Science, suggests that a "heterologous prime-boost" vaccine regimen--which first primes the immune system, then boosts the immune system to increase the response, could ultimately prove to be a strategy for protecting against global human immunodeficiency virus (HIV-1) infection. These data form the basis of vaccine regimens that are now being evaluated in an international phase 1/2a clinical trial for safety and immunogenicity in healthy, HIV-uninfected volunteers. The pre-clinical study published evaluated the protective efficacy of a "prime-boost" vaccine approach, which leverages AdVac Technology from Janssen and a trimeric envelope protein boost. Non-human primates (NHP) were first given an adenovirus serotype 26 (Ad26) vectored vaccine to prime the immune system, and then a boost of a purified HIV envelope protein intended to enhance the immune system over time. This approach is intended to increase both the magnitude of the immune response and the overall protection against subsequent viral challenge. A heterologous prime-boost vaccine regimen using a similar AdVac vector, along with an MVA-based vector, is being used in Janssen's preventative Ebola candidate vaccine regimen that is currently in Phase 1 human clinical studies.
Johnson & Johnson's Global Surgery Group Presents at Medical Device Conference 2015, Jun-26-2015 04:00 PM
Jun 22 15
Johnson & Johnson's Global Surgery Group Presents at Medical Device Conference 2015, Jun-26-2015 04:00 PM. Venue: Palace Hotel, 2 New Montgomery Street, San Francisco, California, United States. Speakers: Jennifer M. Kozak, Vice President, New Business Development & Strategic Planning.
Roche And Johnson & Johnson Eyes Stake In GlaxoSmith
Jun 22 15
Swiss-based Roche Holding AG (SWX:ROG) and U.S.-based Johnson & Johnson are eying the U.K. company for approximately $143 billion. Moreover, there is also a rumor that Pfizer Limited (BSE:500680) was considering acquiring GlaxoSmithKline plc (LSE:GSK) a year after it failed to acquire AstraZeneca PLC. As per the poll conducted by BioSpace, AstraZeneca PLC could also be in the race to acquire struggling GlaxoSmithKline.
Roche, Pfizer, Johnson & Johnson And AstraZeneca In Race To Acquirer GlaxoSmithKline
Jun 22 15
Roche Holding AG (SWX:ROG) and Johnson & Johnson (NYSE:JNJ) are looking to buy GlaxoSmithKline plc (LSE:GSK) ('Glaxo') for approximately $143 billion. There is rumor that Pfizer Limited (BSE:500680) may also be considering acquiring Glaxo. As per the poll conducted by BioSpace, AstraZeneca plc (LSE:AZN) could also be in the race to acquire struggling GlaxoSmithKline.